111.51
price down icon0.20%   -0.22
after-market Dopo l'orario di chiusura: 110.74 -0.77 -0.69%
loading
Precedente Chiudi:
$111.73
Aprire:
$111.79
Volume 24 ore:
5.99M
Relative Volume:
0.67
Capitalizzazione di mercato:
$136.94B
Reddito:
$28.73B
Utile/perdita netta:
$5.97B
Rapporto P/E:
23.48
EPS:
4.75
Flusso di cassa netto:
$9.84B
1 W Prestazione:
+5.27%
1M Prestazione:
+2.39%
6M Prestazione:
+21.36%
1 anno Prestazione:
+63.03%
Intervallo 1D:
Value
$111.09
$112.83
Intervallo di 1 settimana:
Value
$105.79
$112.83
Portata 52W:
Value
$66.01
$119.96

Gilead Sciences Inc Stock (GILD) Company Profile

Name
Nome
Gilead Sciences Inc
Name
Telefono
(650) 574-3000
Name
Indirizzo
333 LAKESIDE DR, FOSTER CITY, CA
Name
Dipendente
17,600
Name
Cinguettio
@GileadSciences
Name
Prossima data di guadagno
2025-02-11
Name
Ultimi documenti SEC
Name
GILD's Discussions on Twitter

Confronta GILD con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Drug Manufacturers - General icon
GILD
Gilead Sciences Inc
111.51 136.94B 28.73B 5.97B 9.84B 4.75
Drug Manufacturers - General icon
LLY
Lilly Eli Co
779.28 724.64B 49.00B 11.11B -1.27B 12.29
Drug Manufacturers - General icon
JNJ
Johnson Johnson
155.56 376.43B 89.33B 21.81B 18.57B 8.99
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
69.82 352.49B 43.59B 15.04B 10.74B 3.3766
Drug Manufacturers - General icon
ABBV
Abbvie Inc
190.75 334.73B 57.37B 4.20B 15.39B 2.35
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
123.81 234.21B 53.22B 12.86B 14.85B 6.39

Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-04-22 Ripresa Cantor Fitzgerald Overweight
2025-03-04 Reiterato Oppenheimer Outperform
2025-02-18 Aggiornamento Deutsche Bank Hold → Buy
2025-02-13 Aggiornamento DZ Bank Hold → Buy
2025-01-10 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2024-12-10 Ripresa BofA Securities Buy
2024-11-15 Iniziato Wolfe Research Outperform
2024-11-14 Iniziato Citigroup Buy
2024-11-08 Downgrade Maxim Group Buy → Hold
2024-10-21 Aggiornamento Leerink Partners Market Perform → Outperform
2024-10-17 Iniziato Bernstein Outperform
2024-10-07 Aggiornamento Wells Fargo Equal Weight → Overweight
2024-07-08 Aggiornamento Raymond James Mkt Perform → Outperform
2024-05-01 Reiterato Maxim Group Buy
2024-04-24 Aggiornamento HSBC Securities Reduce → Hold
2024-02-22 Downgrade Truist Buy → Hold
2023-11-09 Iniziato Deutsche Bank Hold
2023-09-08 Aggiornamento BofA Securities Neutral → Buy
2023-09-06 Iniziato HSBC Securities Reduce
2023-07-24 Reiterato Barclays Equal Weight
2023-05-16 Aggiornamento BMO Capital Markets Market Perform → Outperform
2023-04-28 Ripresa Piper Sandler Overweight
2023-01-03 Downgrade RBC Capital Mkts Outperform → Sector Perform
2022-12-13 Ripresa BofA Securities Neutral
2022-12-09 Downgrade DZ Bank Buy → Hold
2022-10-31 Aggiornamento Barclays Underweight → Equal Weight
2022-10-28 Reiterato BMO Capital Markets Market Perform
2022-10-28 Reiterato Cowen Outperform
2022-10-28 Reiterato JP Morgan Overweight
2022-10-28 Reiterato Jefferies Buy
2022-10-28 Aggiornamento Piper Sandler Neutral → Overweight
2022-10-28 Reiterato RBC Capital Mkts Outperform
2022-10-28 Aggiornamento Truist Hold → Buy
2022-10-28 Reiterato Wells Fargo Equal Weight
2022-10-04 Aggiornamento JP Morgan Neutral → Overweight
2022-07-13 Iniziato Cantor Fitzgerald Neutral
2022-05-23 Iniziato SVB Leerink Mkt Perform
2022-02-28 Downgrade BMO Capital Markets Outperform → Market Perform
2022-02-02 Reiterato BMO Capital Markets Outperform
2022-02-02 Reiterato BofA Securities Neutral
2022-02-02 Reiterato RBC Capital Mkts Outperform
2022-02-02 Reiterato Truist Hold
2022-02-02 Reiterato Wells Fargo Equal Weight
2022-01-28 Aggiornamento Argus Hold → Buy
2022-01-06 Downgrade Morgan Stanley Overweight → Equal-Weight
2021-12-09 Ripresa Wells Fargo Equal Weight
2021-12-06 Iniziato Goldman Neutral
2021-11-19 Aggiornamento BMO Capital Markets Market Perform → Outperform
2021-11-19 Ripresa Piper Sandler Neutral
2021-10-20 Ripresa Cowen Outperform
2021-07-30 Reiterato BMO Capital Markets Market Perform
2021-07-30 Reiterato RBC Capital Mkts Outperform
2021-04-01 Aggiornamento Bernstein Mkt Perform → Outperform
2021-03-30 Aggiornamento Redburn Neutral → Buy
2021-01-19 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2021-01-04 Aggiornamento Guggenheim Neutral → Buy
2020-11-03 Ripresa Morgan Stanley Equal-Weight
2020-10-28 Iniziato UBS Neutral
2020-09-30 Ripresa Jefferies Buy
2020-09-15 Aggiornamento Maxim Group Hold → Buy
2020-07-31 Reiterato Credit Suisse Neutral
2020-07-31 Reiterato Morgan Stanley Equal-Weight
2020-07-31 Reiterato Piper Sandler Overweight
2020-07-31 Reiterato RBC Capital Mkts Outperform
2020-07-31 Reiterato SunTrust Hold
2020-07-31 Reiterato Wells Fargo Equal Weight
2020-07-20 Aggiornamento Credit Suisse Underperform → Neutral
2020-06-03 Aggiornamento SVB Leerink Mkt Perform → Outperform
2020-05-26 Aggiornamento SunTrust Sell → Hold
2020-05-01 Downgrade JP Morgan Overweight → Neutral
2020-05-01 Downgrade Raymond James Outperform → Mkt Perform
2020-05-01 Downgrade SunTrust Hold → Sell
2020-04-27 Downgrade UBS Buy → Neutral
2020-04-20 Downgrade BMO Capital Markets Outperform → Market Perform
2020-04-20 Downgrade Wells Fargo Overweight → Equal Weight
2020-04-17 Downgrade CFRA Hold → Sell
Mostra tutto

Gilead Sciences Inc Borsa (GILD) Ultime notizie

pulisher
Jun 19, 2025

Gilead Sciences Lands First FDA Approval of a Twice-a-Year HIV PrEP Drug - MedCity News

Jun 19, 2025
pulisher
Jun 18, 2025

US FDA approves Gilead's twice-yearly injection for HIV prevention - Deccan Herald

Jun 18, 2025
pulisher
Jun 18, 2025

US approves Gilead’s twice-yearly injection to prevent HIV - The Malaysian Reserve

Jun 18, 2025
pulisher
Jun 18, 2025

US approves Gilead's twice-yearly injection to prevent HIV - El Paso Inc.

Jun 18, 2025
pulisher
Jun 18, 2025

The world's only twice-a-year shot to prevent HIV could stop transmission — if people can get it - Shelton Herald

Jun 18, 2025
pulisher
Jun 18, 2025

Gilead Sciences facility video - KTIV

Jun 18, 2025
pulisher
Jun 18, 2025

HIV prevention drug lenacapavir approved by FDA as twice-yearly injection - CBS News

Jun 18, 2025
pulisher
Jun 18, 2025

FDA approves Gilead's twice-yearly HIV prevention shot - FirstWord Pharma

Jun 18, 2025
pulisher
Jun 18, 2025

Gilead Wins Historic Approval for Twice-Yearly HIV Drug - BioSpace

Jun 18, 2025
pulisher
Jun 18, 2025

HIV advance: Twice-yearly shot to prevent infection - NZ Herald

Jun 18, 2025
pulisher
Jun 18, 2025

Cautious Optimism for Gilead Sciences Amid Yeztugo’s Market Challenges - TipRanks

Jun 18, 2025
pulisher
Jun 18, 2025

Gilead's twice-yearly PrEP drug is cleared by FDA - pharmaphorum

Jun 18, 2025
pulisher
Jun 18, 2025

FDA approves twice-yearly shot of Gilead drug for HIV prevention - BioPharma Dive

Jun 18, 2025
pulisher
Jun 18, 2025

Gilead's HIV Prevention Drug Is 99.9% Effective. Could Politics Derail It? - Investor's Business Daily

Jun 18, 2025
pulisher
Jun 18, 2025

US Approves Gilead's Twice-yearly Injection To Prevent HIV - Barron's

Jun 18, 2025
pulisher
Jun 18, 2025

FDA Approves Gilead’s Twice-Yearly Injection for HIV Prevention - The Well News

Jun 18, 2025
pulisher
Jun 18, 2025

FDA approves 6-month HIV prevention shot - The Hill

Jun 18, 2025
pulisher
Jun 18, 2025

Gilead's (GILD) HIV Treatment Yeztugo Gains FDA Approval, Market Potential Expands | GILD Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

FDA Approval Boosts Gilead's (GILD) Prospects in HIV Prevention | GILD Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Gilead Sciences stock steady as FDA approves twice-yearly HIV prevention - Investing.com UK

Jun 18, 2025
pulisher
Jun 18, 2025

Mizuho says Gilead Yeztugo label looks clean - TipRanks

Jun 18, 2025
pulisher
Jun 18, 2025

Gilead Sciences (GILD) Gains FDA Nod for HIV Prevention Drug - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

FDA Approves Gilead’s HIV Shot. It Works 99.9% of the Time. - Barron's

Jun 18, 2025
pulisher
Jun 18, 2025

Gilead Sciences’ Yeztugo Approval and Market Expansion Drive Buy Rating - TipRanks

Jun 18, 2025
pulisher
Jun 18, 2025

FDA approves powerful HIV prevention drug: What to know about Yeztugo - NBC News

Jun 18, 2025
pulisher
Jun 18, 2025

FDA approves the world’s only twice-a-year shot to prevent HIV - mypanhandle.com

Jun 18, 2025
pulisher
Jun 18, 2025

FDA Approves Gilead’s Twice-Yearly Injectable Lenacapavir (Yeztugo) for HIV Prevention - ContagionLive

Jun 18, 2025
pulisher
Jun 18, 2025

Gilead’s twice-yearly PrEP injection wins FDA approval, analysts see solid launch ahead - Proactive financial news

Jun 18, 2025
pulisher
Jun 18, 2025

Gilead Sciences' HIV Prevention Drug Yeztugo Receives FDA Approval - MarketScreener

Jun 18, 2025
pulisher
Jun 18, 2025

Gilead (GILD) Gains FDA Approval for Unique HIV Prevention Drug Yeztugo | GILD Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Gilead announces FDA approves Yeztugo as twice-a-year HIV prevention option - TipRanks

Jun 18, 2025
pulisher
Jun 18, 2025

Gilead’s Twice-a-Year HIV Prevention Shot Wins US FDA Approval - Bloomberg.com

Jun 18, 2025
pulisher
Jun 18, 2025

Yeztugo® (Lenacapavir) Is Now the First and Only FDA-Approved HIV Prevention Option Offering 6 Months of Protection - marketscreener.com

Jun 18, 2025
pulisher
Jun 18, 2025

Gilead's (GILD) Lenacapavir Advances as HIV Prevention Treatment - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Gilead (GILD) Gains FDA Approval for HIV Prevention Injection | - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Gilead’s twice-yearly HIV prevention shot gets FDA approval - Investing.com Australia

Jun 18, 2025
pulisher
Jun 18, 2025

US FDA approves Gilead’s twice-yearly injection for HIV prevention By Reuters - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

Gilead’s twice-yearly HIV prevention shot gets FDA approval By Investing.com - Investing.com Canada

Jun 18, 2025
pulisher
Jun 18, 2025

Gilead stock gains on FDA nod for HIV PrEP drug (GILD:NASDAQ) - Seeking Alpha

Jun 18, 2025
pulisher
Jun 18, 2025

FDA approves Gilead's twice-yearly HIV prevention injection, offering a powerful and convenient new option - CNBC

Jun 18, 2025
pulisher
Jun 18, 2025

Gilead won U.S. approval for HIV prevention shot, but when will low-income countries gain sufficient access? - STAT

Jun 18, 2025
pulisher
Jun 18, 2025

FDA Says Gilead's Yeztugo Receives FDA Approval For HIV Prevention - marketscreener.com

Jun 18, 2025
pulisher
Jun 18, 2025

Gilead Researcher Awarded the AAAS Mani L. Bhaumik Breakthrough of the Year Award - CSRwire

Jun 18, 2025
pulisher
Jun 18, 2025

Buy, Sell, Or Hold GILD Stock? - Trefis

Jun 18, 2025
pulisher
Jun 18, 2025

Gilead Sciences, Inc. (GILD) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

Jun 18, 2025
pulisher
Jun 18, 2025

Fibrotic Diseases Treatment Market Top Companies StudyAbbVie - openPR.com

Jun 18, 2025
pulisher
Jun 18, 2025

Gilead's HIV drug could end epidemic, but the company has a dark side - Fast Company

Jun 18, 2025
pulisher
Jun 17, 2025

Insider Sell: Andrew Dickinson Sells 2,500 Shares of Gilead Sciences Inc (GILD) - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Gilead's HIV Prevention Drug Could Be Manufactured At Shocking Low Cost: ReportGilead Sciences (NASDAQ:GILD) - Benzinga

Jun 17, 2025
pulisher
Jun 17, 2025

Gilead (GILD) Downplays FDA Decision to Pause HIV Combination Trial over Safety Concern - Insider Monkey

Jun 17, 2025
pulisher
Jun 16, 2025

Levi & Korsinsky Investigates Gilead Sciences, Inc. (GILD) Over Possible Securities Fraud - ACCESS Newswire

Jun 16, 2025

Gilead Sciences Inc Azioni (GILD) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
drug_manufacturers_general PFE
$25.32
price up icon 1.12%
drug_manufacturers_general SNY
$49.31
price up icon 0.53%
$296.85
price up icon 2.18%
drug_manufacturers_general MRK
$82.39
price up icon 0.71%
drug_manufacturers_general NVS
$123.81
price up icon 0.58%
Capitalizzazione:     |  Volume (24 ore):